Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Syntactx | NETWORK |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to evaluate the impact of pharmacogenomic aspects of drug metabolism on the measurement of drug and drug metabolites on urine drug testing (UDT).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Influence of CYP450 drug metabolism on quantitative UDT | Occurrence of genetically-determined abnormal metabolism of drugs tested with UDT, classified as genetic effects on metabolism (GEM) + for rapid metabolizers, GEM 0 for normal metabolizers, and GEM - for slow metabolizers. | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of illicit drugs detected on UDT and the GEM classification associated with these medications | 24 months | |
| Non-prescribed drugs detected on UDT and the GEM classification associated with these medications | 24 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Male and female subjects who are considered candidates for UDT.
Not provided
Not provided
Not provided
Not provided
Not provided
| False positive immunoassay results, defined as positive immunoassay concurrent with negative quantitative testing | 24 months |
| Frequency of target drug regimen changes by the treating physician due to pharmacogenomic test results | 24 months |
| Frequency of illicit drug changes by the subject due to UDT results, as observed at the time of repeat UDT | 24 months |
| Frequency of non-prescribed drug changes by the subject due to UDT results, as detected at the time of repeat UDT | 24 months |